BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hall RG, Cole TJ, Shaw C, Alvarez CA. The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts. Antibiotics 2022;11:295. [DOI: 10.3390/antibiotics11030295] [Reference Citation Analysis]
2 Long MD, Bajaj JS. The American Journal of Gastroenterology in 2022 and Beyond: A Vision for "Our" Journal. Am J Gastroenterol 2021. [PMID: 34904963 DOI: 10.14309/ajg.0000000000001579] [Reference Citation Analysis]
3 Baus CJ, Schulz LT, Lepak AJ, Safdar N. Letter to the Editor: Response to Maziade et al; Enhanced Clostridioides difficile infection prevention with a pharmacy-controlled policy that adds a three-strain Lactobacillus probiotic concomitantly to antibiotic therapy. Clin Infect Dis 2021:ciab661. [PMID: 34320158 DOI: 10.1093/cid/ciab661] [Reference Citation Analysis]
4 Feuerstadt P, Nelson WW, Drozd EM, Dreyfus J, Dahdal DN, Wong AC, Mohammadi I, Teigland C, Amin A. Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults. Journal of the American Medical Directors Association 2022. [DOI: 10.1016/j.jamda.2022.01.075] [Reference Citation Analysis]
5 Cold F, Svensson CK, Petersen AM, Hansen LH, Helms M. Long-Term Safety Following Faecal Microbiota Transplantation as a Treatment for Recurrent Clostridioides difficile Infection Compared with Patients Treated with a Fixed Bacterial Mixture: Results from a Retrospective Cohort Study. Cells 2022;11:435. [DOI: 10.3390/cells11030435] [Reference Citation Analysis]
6 Gomez SY, Patel J, Lopez CA. What's metal got to do with it? Transition metals in Clostridioides difficile infection. Curr Opin Microbiol 2021;65:116-22. [PMID: 34839238 DOI: 10.1016/j.mib.2021.11.004] [Reference Citation Analysis]
7 Johnson TM, Molina KC, Howard AH, Schwarz K, Allen L, Huang M, Bajrovic V, Miller MA. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clin Infect Dis 2021:ciab674. [PMID: 34665248 DOI: 10.1093/cid/ciab674] [Reference Citation Analysis]
8 Monaghan TM, Seekatz AM, Mullish BH, Moore-Gillon CCER, Dawson LF, Ahmed A, Kao D, Chan WC. Clostridioides difficile: innovations in target discovery and potential for therapeutic success. Expert Opin Ther Targets 2021;:1-15. [PMID: 34793686 DOI: 10.1080/14728222.2021.2008907] [Reference Citation Analysis]
9 Carlson TJ, Gonzales-Luna AJ, Garey KW. Fulminant Clostridioides difficile Infection: A Review of Treatment Options for a Life-Threatening Infection. Semin Respir Crit Care Med 2022;43:28-38. [PMID: 35172356 DOI: 10.1055/s-0041-1740973] [Reference Citation Analysis]
10 Freedman SB, Tarr PI, Tougas S. Increasing Incidence of Pediatric Clostridioides difficile Colonization-More Exploration Is Needed-Reply. JAMA Pediatr 2021. [PMID: 34807240 DOI: 10.1001/jamapediatrics.2021.4744] [Reference Citation Analysis]
11 Sood N, Carbell G, Greenwald HS, Friedenberg FK. Is the Medium Still the Message? Culture-Independent Diagnosis of Gastrointestinal Infections. Dig Dis Sci 2021. [PMID: 34846676 DOI: 10.1007/s10620-021-07330-6] [Reference Citation Analysis]
12 Wang L, Li D, Chen Z, He L, Wang X, Tao L. An Atypical Case of Monomicrobial Clostridioides difficile Septicemia With No Gastrointestinal Manifestations. Front Cell Infect Microbiol 2022;12:853252. [DOI: 10.3389/fcimb.2022.853252] [Reference Citation Analysis]
13 Wombwell E, Bransteitter B, Gillen LR. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic. Mycoses 2021;64:1521-6. [PMID: 34585799 DOI: 10.1111/myc.13375] [Reference Citation Analysis]
14 Wu Y, Wang Y, Bai L, Zhang W, Li G, Lu J. A narrative review of Clostridioides difficile infection in China. Anaerobe 2022. [DOI: 10.1016/j.anaerobe.2022.102540] [Reference Citation Analysis]
15 Golčić M, Simetić L, Majnarić T, Golčić G, Herceg D. Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma? Medical Hypotheses 2022. [DOI: 10.1016/j.mehy.2022.110801] [Reference Citation Analysis]
16 Strati F, Lattanzi G, Amoroso C, Facciotti F. Microbiota-targeted therapies in inflammation resolution. Semin Immunol 2022;:101599. [PMID: 35304068 DOI: 10.1016/j.smim.2022.101599] [Reference Citation Analysis]
17 Waller KMJ, Leong RW, Paramsothy S. An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases. J Gastroenterol Hepatol 2021. [PMID: 34735024 DOI: 10.1111/jgh.15731] [Reference Citation Analysis]